Leveraging strategic partnerships to gain marketplace advantages
By Mark Goldberg, M.D., Chief Operating Officer
The competitive and regulatory environments surrounding the biopharmaceutical industry have changed dramatically in the last decade. Companies developing novel therapies have never confronted a more daunting array of challenges, including pricing pressures, rising development costs, R&D inefficiency, constraints on investment capital, increasing regulatory hurdles, and the need to demonstrate product value to maximize market access. Read More.
Q&A with Mario Papillon, VP, Strategic Account Leader
What is fueling the growth in strategic partnerships between biopharmaceutical companies and service providers?
Faced with continuing financial and competitive pressures, many biopharmaceutical companies are exploring new types of strategic partnerships designed to deliver greater benefits throughout the product development lifecycle. This next partnership stage involves longer-term and more-complex relationships with a small number of service partners, focusing on project oversight cost reductions and time savings – the areas of product development where the most valuable improvements can be achieved. Read More.
By Joshua Schultz, Corporate VP, Strategic Account Leader
Facing intense competitive and financial pressures to accelerate product development while continuing to cut costs, many biopharmaceutical companies are moving beyond traditional outsourcing relationships and exploring new types of strategic partnerships designed to deliver a much higher level of benefits throughout the product development lifecycle. Achieving those benefits requires a new partnership paradigm that is characterized by deeper and more-complex relationships between a biopharmaceutical company and a small number of partners – usually no more than two or three. Read More.